tbuckley/cabot-search huggingface dataset:
SAT0450 Impact of Myofascial Pain Syndrome on Pain and Functional Status in Patients with Hand Osteoarthritis
Authors: H.-O. Kim, Y.S. Suh, Y.-H. Cheon, K.S. Park, S.-H. Kim, R.B. Kim, S.-I. Lee
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Various upper extremity musculoskeletal diseases (MSDs) can affect pain and disability in patients with hand osteoarthritis (HOA). However, there was no previous study investigating the relationship between upper extremity MSDs and HOA. <h3>Objectives</h3> To explore the influence of major upper extremity MSDs on pain severity and functional status of patients with HOA. <h3>Methods</h3> In this study, we enrolled 1150 farmers who lived in Gyeongnam province in Korea from June 2013 to December 2015. Physical examinations were performed by rheumatologists, orthopedists, and rehabilitation specialists. Grip powers of both hands also were evaluated. Plain radiography, a nerve conduction velocity (NCV) examination, and magnetic resonance imaging (MRI) of shoulders were performed. The Australian/Canadian Osteoarthritis Hand Index (AUSCAN) was used to assess pain severity and functional status of hand joints. The diagnosis of HOA was made by the 1990 American College of Rheumatology classification criteria. Carpal tunnel syndrome (CTS) was confirmed by NCV findings, and rotator cuff tear (RCT) was diagnosed by MRI findings. Myofascial pain syndrome (MPS) was diagnosed by palpations of myofascial trigger points. <h3>Results</h3> Of 1150 participants, 307 were diagnosed with HOA. Among HOA patients, 151 (49.7%), 192 (62.5%), and 249 (80.1%) patients had CTS, RCTs, and MPS, respectively. HOA patients with MPS showed significantly higher AUSCAN scores (350.4±285.0 vs 200.4±201.8, p&lt;0.001) and decreased grip power of a dominant hand (22.5±9.8 vs. 26.2±9.8, p=0.011) compared with HOA without MPS. Linear regression analysis also showed that MPS was associated with AUSCAN scores after adjustment for age and gender (β=0.21, p=0.001). The existence of CTS or RCT did not influence on AUSCAN scores and grip power. Compared to participants with none of major upper extremity MSDs, participants with MPS only were also higher AUSCAN scores. <h3>Conclusions</h3> MPS has a significant impact on pain and functional status in patients with HOA. Therefore, management of coexisting MPS is the better way to improve pain and function of hand joints in patients with HOA. <h3>Acknowledgement</h3> This study was supported by a grant of the Center for Farmer9s Safety and Health, Ministry of Agriculture, Food and Rural Affairs, Republic of Korea. <h3>Disclosure of Interest</h3> None declared
AMD3100 Inhibits Chemotaxis towards SDF-1 and CXCR4-Mediated Stroma-Contact in a Dose-Dependent Manner, Resulting in Increased Susceptibility to Imatinib.
Authors: Falk M. Dillmann, Marlon R. Veldwijk, Gary Calandra, Werner J. Zeller, Anthony D. Ho, Stefan Fruehauf
Journal: Blood (2006)
FRI0642-HPR Scapular Biomechanics in Patients with Adhesive Capsulitis
Authors: T. Zoroglu, S. Basar
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> It is necessary that coordinated, synchronous motion of humerus, scapula and clavicula for full shoulder mobility and function. This motion may be impaired by adhesive capsulitis (AC) which is characterized by fibrosis and contracture of the glenohumeral joint capsule and ligaments. <h3>Objectives</h3> In this study we aimed to assess scapular biomechanics in patients with adhesive capsulitis and determine changes. <h3>Methods</h3> Twenty five patients with AC (21 female, 4 male; mean age 53±6 years; age range 44–67) and twenty five healthy people (21 female, 4 male; mean age 51±7; age range 39–65) were included in this study. Mean Body Mass Index (BMI) was 29.02±4.89 in AC group (ACG) and 28.40±4.67 in healthy group (HG). 11 dominant and 14 non-dominant shoulders in ACG and 12 dominant and 13 non-dominant shoulders in HG were measured. Kibler9s observational classification system and lateral scapular slide test (LSST) were used for evaluating scapular position and mobility. <h3>Results</h3> There were 2 type I, 8 type II,10 type III and 5 symetric scapula in ACG and 3 type I, 4 type II,7 type III and 11 symetric scapula in HG. 80% of ACG and 56% of HG had scapular dyskinesia but it was not significant (p&gt;0.05). There was significant difference between groups in LSST the distance between inferior angle of scapula and T7 at 90° abduction (p&lt;0.05) (Table 1). <h3>Conclusions</h3> In this study, our results showed that scapular biomechanics were impaired in patients with AC. Especially the majority of type III scapula and the distance between inferior angle of scapula and T7 at 90° abduction demonstrate increase in scapular upward rotation in upper degrees of elevation. <h3>References</h3> Culham, E. and Peat, M. (1993). Functional anatomy of the shoulder complex. The Journal of Orthopaedic and Sports PhysicalTherapy,18 (1), 342–350. Neviaser, A.S. and Hannafin, J.A. (2010). Adhesive capsulitis: A review of current treatment. The American Journal of Sports Medicine, 38(11), 2346–2356. Page, P. and Labbe, A. (2010). Adhesive capsulitis: Use the evidence to integrate your interventions. North American Journal of Sports Pyhsical Therapy, 5(4), 266–273 <h3>Disclosure of Interest</h3> None declared
Microbubble gas volume: A unifying dose parameter in blood-brain barrier opening by focused ultrasound
Authors: Kang-Ho Song, Alexander C. Fan, Joshua J. Hinkle, Joshua Newman, Mark A. Borden, Brandon K. Harvey
Journal: Theranostics (2016)

Focused ultrasound with microbubbles is being developed to transiently, locally and noninvasively open the blood-brain barrier (BBB) for improved pharmaceutical delivery.Prior work has demonstrated that, for a given concentration dose, microbubble size affects both the intravascular circulation persistence and extent of BBB opening.When matched to gas volume dose, however, the circulation half-life was found to be independent of microbubble size.In order to determine whether this holds true for BBB opening as well, we independently measured the effects of microbubble size (2 vs. 6 µm diameter) and concentration, covering a range of overlapping gas volume doses (1-40 µL/kg).We first demonstrated precise targeting and a linear dose-response of Evans Blue dye extravasation to the rat striatum for a set of constant microbubble and ultrasound parameters.We found that dye extravasation increased linearly with gas volume dose, with data points from both microbubble sizes collapsing to a single line.A linear trend was observed for both the initial sonication (R 2 =0.90) and a second sonication on the contralateral side (R 2 =0.68).Based on these results, we conclude that microbubble gas volume dose, not size, determines the extent of BBB opening by focused ultrasound (1 MHz, ~0.5 MPa at the focus).This result may simplify planning for focused ultrasound treatments by constraining the protocol to a single microbubble parameter -gas volume dose -which gives equivalent results for varying size distributions.Finally, using optimal parameters determined for Evan Blue, we demonstrated gene delivery and expression using a viral vector, dsAAV1-CMV-EGFP, one week after BBB disruption, which allowed us to qualitatively evaluate neuronal health.
Fractionated Cyclophosphamide, Vinblastine with Prednisolone and Daily Oral Etoposide Based Treatment of AIDS-Related Plasmablastic Lymphomas (PBL): A Highly Active and Well Tolerated Regimen
Authors: Manju Sengar, Tanuja Shet, Reena Nair, Epari Sridhar, Hari Menon, Sumeet Gujral, Siddhartha Laskar, Aruna Alahari
Journal: Blood (2011)
Development of a Cancer Pharmacopeia-Wide Ex-Vivo Drug Sensitivity and Resistance Testing (DSRT) Platform: Identification of MEK and mTOR As Patient-Specific Molecular Drivers of Adult AML and Potent Therapeutic Combinations with Dasatinib
Authors: Mika Kontro, Caroline Heckman, Evgeny Kulesskiy, Tea Pemovska, Maxim Bespalov, Samuli Eldfors, Elonen Erkki, Riikka Karjalainen, Jonathan Knowles, Disha Malani, Muntasir Mamun Majumder, John Patrick Mpindi, Astrid Murumägi, Satu Mustjoki, Laura Turunen, Maija Wolf, Kimmo Porkka, Krister Wennerberg, Olli Kallioniemi
Journal: Blood (2011)
NF-κB Is Constitutively Activated in EBV-Infected T or NK Cells and Can Be a Molecular Target for EBV-Positive T/NK-Cell Lymphoproliferative Disease Treatment
Authors: Ayako Arai, Mayumi Takahashi, Ken-Ichi Imadome, Takatoshi Koyama, Yasunori Saitoh, Shoji Yamaoka, Shigeyoshi Fujiwara, Osamu Miura
Journal: Blood (2010)
Combination of Oral Deferiprone and Subcutaneous Infusion of Desferrioxamine in Chelating Overloaded Iron in Pediatric Patients with Beta-Thalassemia Disease.
Authors: Ampaiwan Chuansumrit, Nongnuch Sirachainan, Suthep Wanichkul, Duantida Songdej, Pakawan Wongwerawattanakoon, Praguywan Kadegasem
Journal: Blood (2009)
AB0088 Transgenic ZAP-70+ B Cells Mice Show A More Severe Collagen Antibody Induced Arthritis (CAIA) than Wild Type
Authors: F. Biscetti, F. Angelini, S. Gobessi, E. Gremese, B. Tolusso, D. Efremov, G. Ferraccioli
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Zeta-chain-associated protein kinase 70 (ZAP-70), a tyrosine kinase constitutively expressed in T cells, can be found in B cells and is used as a prognostic marker in identifying different forms of chronic lymphocytic leukemia. We previously provided evidence that a subset of B cells in patients with rheumatoid arthritis (RA) expresses ZAP-70, that marks the memory B cell subsets (IgD+CD27+ and IgD-CD27+), thus suggesting that the ZAP-70+ B cells represent a memory activated subset likely involved in the maintenance of an activated B cell pool [1–3]. <h3>Objectives</h3> The aim of the present study was to clarify whether B cells, especially ZAP-70 expressing B cells, represent indeed a risk for a severe expression of arthritis in a transgenic ZAP-70+B murine model. <h3>Methods</h3> Male transgenic ZAP-70+B mice, that has already been shown to present an high ZAP-70 expression in the B cell lineage [4], aged 8–12 weeks old were used for experiments. All the animals were injected with a cocktail of 5 monoclonal antibodies recognizing the conserved epitopes on various species of type II collagen. Three days later the mice were injected with LPS from <i>E. coli</i> 0111:B4 to trigger arthritis development. Animals were evaluated every 3 days after the infusion of the antibody cocktail for arthritis incidence and each paw was evaluated and scored individually on a scale of 0–4. An arthritis index (AI) that expressed a cumulative score for all paws was calculated for each animal. <h3>Results</h3> We found that the transgenic ZAP-70+B cells mice presented a more severe form of arthritis, compared to wild type age-matched mice (p&lt;0.001) (Figure). Histological and immunohistochemical analyses confirmed the presence of joint erosions and inflammatory infiltrate at the level of the synovium of ZAP-70+B cells mice. <h3>Conclusions</h3> These data suggest that B cells amplify the degree of CAIA, that ZAP-70 is involved in the pathogenesis of arthritis in an RA-like model, and that this tyrosine kinase likely represents a possible target of therapy. <h3>References</h3> Tolusso B, et al. Clin Immunol. 2009 Apr;131(1):98–108 Michelutti A, et al. Mol Med. 2011 Sep-Oct;17(9–10):901–9 Gremese E, et al. J Rheumatol. 2012 Dec;39(12):2276–85 Gobessi S, et al. Blood (ASH Annual Meeting Abstracts) 2011 118: Abstract 2830? <h3>Disclosure of Interest</h3> None declared
SP0099 Awareness and Use of Objective and Subjective Assessments of Physical Activity among Health Professionals and Barriers for Implementation
Authors: B. Nordgren
Journal: Annals of the Rheumatic Diseases (2016)

It is widely acknowledged that regular physical activity confers multiple health benefits in people with inflammatory rheumatic diseases. Participation in physical activity should therefore be encouraged by health professionals. Despite recognising the importance of physical activity, health professionals frequently fail to provide advice on promoting same. As advice alone is not always translated into behavior, subjective and objective measures of both physical activity and sedentary behaviour are important in order to motivate change in behaviour. Questionnaires, diaries, pedometers, accelerometers and multi-sensor devices are example of useful tools for assessing and monitoring progress of physical activity in clinic and research trials. However, health professionals awareness and use of such instruments in a clinical setting, in addition to barriers for not using same to date, has been scarcely described, and will be highlighted during this session. Data from an international cross-sectional study, describing the awareness and use of objective and subjective measures of physical activity, as well as barriers for implementation of such methods in health professionals working with patients with inflammatory arthritis in Sweden, Ireland, Denmark and Belgium, will be presented. <h3>Disclosure of Interest</h3> None declared
Conditional Deletion of the Hoxa Cluster in MLL-AF9 Is Incompatible with Leukemia Maintenance
Authors: Laura M Kettyle, Ivan Grishagin, Glenda J Dickson, Charles-Etienne Lebert-Ghali, Janetta Jacoba Bijl, Mary Frances McMullin, Terence R.J. Lappin, Ken I Mills, Alexander Thompson
Journal: Blood (2015)
SGN-CD123A, a Pyrrolobenzodiazepine Dimer Linked Anti-CD123 Antibody Drug Conjugate, Demonstrates Effective Anti-Leukemic Activity in Multiple Preclinical Models of AML
Authors: May S.K. Sutherland, Changpu Yu, Roland B. Walter, Lori Westendorf, John Valliere-Douglass, Lucy Pan, Django Sussman, Martha Anderson, Weiping Zeng, Ivan Stone, Kerry Klussman, Michelle Ulrich, Mechthild Jonas, Peter Senter, Jonathan G. Drachman, Dennis Benjamin
Journal: Blood (2015)
The Impact of Genetic Abnormalities (GA) and Other Factors on Survival in Patients after 65 Years with Multiple Myeloma (MM)
Authors: Andrei Garifullin, Irina Martynkevich, Sergei Voloshin, Alexei Kuvshinov, Ludmila Martynenko, Elizaveta Kleina, Galina Salogub, Elena Karyagina, Alexander Schmidt, Kudrat Abdulkadyrov
Journal: Blood (2015)
PTU-074 Vedolizumab in Primary and Autoimmune Sclerosing Cholangitis Associated Inflammatory Bowel Disease Pre and Post Liver Transplantation: A Case Series
Authors: TY Lim, P Pavlidis, T Pirani, S Gulati, M Samaan, G Chung-Faye, P Dubois, P Irving, B Hayee
Journal: Gut (2016)

<h3>Introduction</h3> Vedolizumab has been recently licensed by NICE for the management of moderate to severe inflammatory bowel disease (IBD). Currently, no data is available on the efficacy or safety of this treatment in the context of autoimmune liver disease (AILD) associated IBD, especially in those post-liver transplantation (LT). <h3>Methods</h3> Case series from two UK, tertiary IBD centres. Patients with primary and autoimmune sclerosing cholangitis (PSC and AISC) associated IBD were identified from a prospectively kept database. Clinical activity was assessed using Harvey-Bradshaw Index (HBI) or Simple Clinical Colitis Activity Index (SCCAI) at baseline and end of follow up (response: drop in HBI/SCCAI &gt;3, remission: HBI &lt; 5, SCCAI &lt;3). Quality of life (QoL) was assessed by the IBD-control-8 questionnaire. Continuous data are summarised as medians followed by range. Pre- and post-induction values were compared using the Wilcoxon test. <h3>Results</h3> We identified 10 patients with ulcerative colitis (UC) and AILD. The median age was 33 years (19, 57), with a follow up of 6 months (3, 13). There were 6 patients with PSC and 4 with AISC [5 (50%) postLT)]. Clinical and/or endoscopically [Mayo score: 2 (2,3)] active disease was the indication for vedolizumab initiation in all patients with 7 (70%) having failed antiTNFα therapy before. Concomitant medication included: Tacrolimus: 4 (40%), Prednisolone: 7 (70%), MMF: 2 (20%), Azathioprine: 2 (20%) and Mercaptopurine: 1 (10%). A clinical response was seen in 4/10 (40%) and one patient achieved clinical remission. Surgery was required for one patient during induction due to severe colitis. A drop in faecal calprotectin [667 (60, 1080) vs. 182 (20, 349), p = 0.06] and improvement in QoL were observed [5 (0, 13) vs. 13 (8, 16), p = 0.03]. There were no infectious or other identified adverse events associated to vedolizumab. <h3>Conclusion</h3> Vedolizumab appears to be a safe treatment in IBD patients with AILD pre- and post-LT and appears to have reasonable efficacy even for difficult-to-treat luminal disease. <h3>Disclosure of Interest</h3> None Declared
High Busulfan Exposure Is Associated with Worse Outcome in a Daily IV Busulfan and Fludarabine Transplant Regimen.
Authors: Michelle Geddes, Shahbal B. Kangarloo, Farrukh Naveed, Quinlan M. Diana, Ahsan Chaudhry, Mary Lynn Savoie, Nizar J. Bahlis, Douglas A. Stewart, Christopher Brown, Jan Storek, Borje Andersson, James A. Russell
Journal: Blood (2006)
An Escalated Dose of Bortezomib Plus Second Line Chemotherapy for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma,
Authors: Yongqian Jia, Bing Xiang, Xiaodong Wang, Jianjun Li, Chuan He, Yi Su, Hong Lu, Ting Niu, Jie Huang, Xinchuan Chen, Xu Cui, Yuping Gong, Huanling Zhu, Ting Liu
Journal: Blood (2011)
AB0393 Metothrexate plus Leflunomide Step-Up Therapy in Early Rheumatoid Arthritis Patients with Non Response To Initial Methotrexate in Monotherapy
Authors: L.R. Carlevaris
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Treatment of patients with rheumatoid arthritis (RA) must be directed to remission, and in some patients minimum activity, can be an option. The strategy most studied is the early and intensive treatment, associated with a strict monitoring. Half of these patients respond to initial monotherapy with methotrexate (MTX), and in non-responders, additive treatments with other synthetic DMARDs are an option. The utility of the combined and additive strategy (Step-up) of MTX and Leflunomide (LEF) is not well defined in early RA. <h3>Objectives</h3> The objectives of this study was to estimate theproportion of clinical remission achieve by the Step-up strategy with LEF in patients with early RA that did not respond to initial monotherapy with MTX, the time to achieve remission, and estimate the state of remission in the last follow-up evaluation. <h3>Methods</h3> An observational study of consecutive case series was performed by including a cohort of patients from Early Arthritis Argentine Consortium (CONAART) with RA of less than 2 years of disease duration, with no response to MTX in monotherapy according to medical judgment, and in whom treatment was additive with LEF. Assessment and data collection was performed every 3 months. Sociodemographic characteristics, functional status, disease activity and treatment were included. “Time to result” was assessed since the date of the beginning with the combination of MTX plus LEF to remission or last control. The state of remission was evaluated by DAS28. The Kaplan-Meier method was used to estimate the probability of each outcome. <h3>Results</h3> A total of 106 patients were included. The mean duration of the disease at the time of inclusion was 4 months (IQR 2–8). The average age was 50±12 years and 83% were women. 68% were positive for RF and 65% for CCP. Median follow-up was 34±18 months (300 patient-years). After addition of LEF, 95 (90%) patients weren9t in remission. The mean DAS28 was 4.61 (±1.61), HAQ =0.9 (±0.76), dose of prednisone =7.31 (±4.25). The median time in months of use of MTX was 6.7 (IQR 3.4–14.4), and 64% had doses greater than 20 mg of MTX during follow-up, 47 (50%) of patients achieved clinical remission in an average time of 8 months. The remaining patients did not achieve remission. The overall probability of remission for patients-month follow-up was 0.49. Twenty-seven of the 47 patients (58%) were still in remission at the last visit. Median follow-up after achieving remission was 20 months (IQR 3–29). <h3>Conclusions</h3> In this early RA cohort study, 50% of patients with lack of response to MTX who added LEF achieved remission assessed by DAS28 at a median time of 8 months. 6 out of 10 of these patients were in remission at 2 years of follow-up. <h3>Disclosure of Interest</h3> None declared
Stayin’ Alive in the Neonatal Intensive Care Unit
Authors: Katie Lockwood
Journal: JAMA Pediatrics (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
OP0086 Which Cells Correspond To The Typical Signals for Fatty and Inflammatory Lesions Seen in Magnetic Resonance Imaging in Ankylosing Spondylitis? A Prospective Study Using Biopsy Material Obtained during Spinal Surgery -
Authors: X. Baraliakos, H. Boehm, A. Samir, G. Schett, J. Braun
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The occurrence of bone marrow edema (BME) and fat metaplasia detected by magnetic resonance imaging (MRI) were shown to be significantly associated with syndesmophyte formation in patients with ankylosing spondylitis (AS). The cell type responsible for the fat signal seen in MRI has not been defined to date. <h3>Objectives</h3> To histologically analyze the cells seen in fatty lesions (FL) as detected by MRI in spinal biopsies of AS patients and compare them with controls. <h3>Methods</h3> Spinal biopsies from vertebral edges of patients with AS and controls who underwent surgery for spinal deformity or spinal stenosis were prospectively collected. All patients had spinal STIR- and T1-weighted MRIs available exactly from the area of biopsy, and all biopsies were taken from areas that had a fat signal on MRI. The biopsies were analysed blinded to patients9 diagnosis. Histomorphological analyses were performed to detect normal bone marrow, fat cells, inflammatory cells and fibroblasts. Histologic results were compared with MRI findings. <h3>Results</h3> Biopsies mostly obtained from the lower thoracic and the lumbar spine of 13 AS patients (mean age 56.3 years, mean disease duration 26 years) and 6 controls (mean age 53.4 years) were available. Similar proportions of AS patients, (12/16, 75%) and non-AS patients (4/6, 67%) had vital bone marrow. Fat cells were found in all 13 biopsies obtained from AS patients from the area of the fat signal vs. only 2 non-AS patients (33%), while inflammatory cells were found in 9 AS patients (56.3%), all of which also had BME on MRI, vs. 3 non-AS patients (50%). Fibroblasts were seen in 3 AS (18.9%) and 2 non-AS patients (33%). <h3>Conclusions</h3> The underlying cell types of FL and BME as detected by MRI in these long standing AS patients were fatty and inflammatory cells. The main difference between AS and non-AS patients was the proportion of biopsies containing fat cells. This suggests that fat cells are responsible for the MRI signal, at least in patients with longstanding ankylosing spondylitis. <h3>Disclosure of Interest</h3> None declared